CBD and Multiple Sclerosis

Peer-reviewed studies into the potential effects of Cannabidiol and Multiple Sclerosis

On this page, CBD and Multiple Sclerosis, you will find research pertaining to the use of Cannabidiol and Cannabinoids and its possible effects on Multiple Sclerosis (MS). The information below is not meant to influence your opinion, but rather give you access to a wealth of scientific literature in an attempt to make and educated and informed choice. Click Here to see all of the conditions that have been researched alongside CBD and Multiple Sclerosis. If you have any questions pertaining to the research, please email us at info@hempicated.com.

Sativex for the management of multiple sclerosis symptoms.

From the abstract:

Sativex (R) is a cannabis-based pharmaceurical product containing delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio, delivered in an oromucosal (mouth) spray. It has been approved as adjunctive treatment for neuropathic pain in patients with multiple sclerosis (MS)… THC:CBD spray significantly reduced neuropathic pain, spasticity, muscle spasms and sleep disturbances.

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis

From the abstract:

Clinical experience with Sativex in patients with multiple sclerosis is accumulating steadily. Results from randomized, controlled trials have reported a reduction in the severity of symptoms associated with spasticity, leading to a better ability to perform daily activities and an improved perception of patients and their carers regarding functional status when Sativex was added to the current treatment regimen.

Cannabidiol provides long-lasting protection against the deleterious effects of inlfammation in a viral model of multiple sclerosis: a rol for A2A receptors.  

From the abstract:

Together, our findings highlight the anti-inlfammatory effects of CBD in this viral model of [multiple sclerosis] and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component.

Oromucosal delta0-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled open-label. 2-year extension trial.

From the abstract:

THC/CBD was effective, with no evidence of tolerance, in these select patients with [central neuropathic pain] and [multiple sclerosis] who completed approximately 2 years of treatment (n=28).

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis

From the abstract:

Over the last two decades, experimental and clinical data suggest a therapeutic benefit of cannabis-based medicines for a variety of multiple sclerosis (MS) symptoms. Clinical trials, both with synthetic or pland-derived cannabinoids, have demonstrated clinical efficacy of cannabinoids for the treatment of spasticity, neuropathic pain and bladder dysfunction.

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.

From the abstract:

Sativex is an endocannabinoid system modulator principally containing delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). During a 6-week randomised controlled trial, Sativex had a clinically relevant effect on spasticity associated with multiple sclerosis (MS). Patients self-titrated oromucosal Sativex to symptom relief or maximum tolerated dose (maximum of 130 mg THC and 120 mg CBD daily)… No new safety concerns were identified with chronic Sativex treatment, and serious [adverse events] were uncommon. There was no evidence of tolerance developing, and patients who remained in the study reported coninued benefit.

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis 

From the abstract:

…Sativex treatment resulted in a significant reduction in treatment-resistant spasticity, in subjects with advanced [multiple sclerosis] and severe spasticity. The response observed within the first 4 weeks of treatment appears to be a useful aid to prediction of responder/non-responder status. 

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain  

From the abstract:

Debilitating pain, occurring in 50-70{03c6ed9c7292793a5635106886a6facae0686a7e7bfbe6c29280aa83fc7d030a} of multiple sclerosis (MS) patients, is poorly understood and infrequently studied. We summarized efficacy and safety data of cannabinoid-based drugs for neuropathic pain… Cannabinoids including the cannabidiol/THC buccal spray are effective in treating neuropathic pain in MS. 

Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain

From the abstract:

Positive results in placebo-controlled trials of the use of Sativex as an add-on therapy in these indications demonstrate that Sativex is efficacious and well tolerated in the treatment of [spasticity and neuropathic pain].

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis

From the abstract:

Pain is a common symptom of [multiple sclerosis (MS)], affecting up to 70{03c6ed9c7292793a5635106886a6facae0686a7e7bfbe6c29280aa83fc7d030a} of patients. Pain treatment is often unsatisfactory, although emerging drugs (including cannabinoids) are giving encouraging results… One month of [Sativex] administration in MS patients with neuropathic pain successfully reduced pain rating and improved quality of life.

Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis

From the abstract:

Our results showed a clear downregulation of the PI3K/Akt/mTOR pathway following [Experimental Autoimmune Encephalomyelitis] induction. CBD treatment was able to restore it, increasing significantly the phosphorylation of PI3K, Akt, and mTOR…our data demonstrated that therapeutic efficacy of CBD treatment is due to reduction of pro-inflammatory cytokines, like IFN-gamma and IL-17 together with an up-regulation of PPARgamma. Finally, CBD was found to promote neuronal survival by inhibiting JNK and p38 MAP kinases. These results provide an interesting discovery about the regulation of the PI3K/Akt/mTOR pathway by cannabidiol administration, that could be anew potential therapeutic target for MS management.

Tetrahydrocannabinol: Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.

From the abstract:

[multiple sclerosis (MS)-related drug-resistant spasticity (MSS)] scores and spasticity-related symptoms (spasms, fatigue, pain, sleep quality and bladder dysfunction) were significantly improved by THC:CBD at 3 months, as were activities of daily living, and [quality of life] (EQ-5D VAS). .. In everyday clinical practice, THC:CBD oromucosal spray provided symptomatic relief of MSS and related troublesome symptoms.

Neurological Aspects of Medical Use of Cannabidiol

From the abstract:

[Cannabindiol] neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of a large number of brain biological targets (receptors, channels) involved in the development and maintenance of neurodegenerative diseases… Pre-clinical evidence largely shows that CBD can produce beneficial effects in [alzeimers disease], Parkinson’s disease and [multiple sclerosis] patients…